Biotech firm’s IONA Test ‘could net billions’

BIOTECH firm Premaitha Health is on the verge of tapping into a multi-billion pound market with its ground breaking non-invasive prenatal screening test for pregnant women.

Chief executive of the Manchester-based company, Dr Stephen Little, told there was already strong demand for the newly-developed IONA test, which detects the risk of Downes Syndrome and other serious genetic diseases in unborn babies.

Little launched the company in 2013, after his previous company DxS was sold to QIAGEN ... For the full story register now for free or login below...